Zanubrutinib and chemo for untreated high-risk follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CHOP) in people with newly diagnosed, intermediate-high risk follicular lymphoma that has not yet been treated. The goal is to see if this combination works better than current standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lymphoma must be a type called follicular lymphoma, grades 1, 2, or 3a (not 3b).
- You should not have had any prior treatment for lymphoma (like chemo or targeted therapy).
- Your lymphoma must need treatment now (meeting GELF criteria) and be stage II, III, or IV.
- You must have an intermediate-high risk score on a test called FLIPI-1 or FLIPI-2.
- Your blood counts and heart/kidney/liver function must be good enough, as checked by standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a new combination of targeted drugs (zanubrutinib, lenalidomide, and rituximab) against a standard two-drug combination for people with newly diagnosed follicular lymphoma who need treatment right away. It aims to see if the three-drug combo is more effective.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with a specific high-risk form of follicular lymphoma who have not yet been treated. The goal is to see if this combination can control the lymphoma more effectively.
Hear when a new FL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.